There are 3162 resources available
How to manage safety
Presenter: Ilaria Colombo
Session: Antibody drug conjugates (ADCs): Are there new therapeutic approaches in gynaecological cancers?
Resources:
Slides
Webcast
Invited Discussant LBA73, LBA74 and LBA75
Presenter: Manuela Schmidinger
Session: Proffered paper session 1: GU tumours, non-prostate
Resources:
Slides
Webcast
Noncoding regions as a source of targetable tumour-specific antigens
Presenter: Sebastian Amigorena
Session: Beyond coding neoantigens: What else is there for T cells to see?
Resources:
Slides
Webcast
Incorporating ctDNA into RECIST v1.1: Steps ahead
Presenter: Elena Garralda
Session: New endpoints in early clinical trials
Resources:
Slides
Webcast
Combinations with IO
Presenter: Jarushka Naidoo
Session: Treating KRAS-mutated NSCLC
Resources:
Slides
Webcast
Q&A and discussion
Session: Improving the assessment of citizens perception of risk
Resources:
Webcast
ESMO-MCBS coming of age: can we extend beyond registration studies?
Presenter: Sjoukje Oosting
Session: ESMO-MCBS: A practical tool with public health implications
Resources:
Slides
Webcast
Invited Discussant 440O, 441O and 442O
Presenter: Emeline Tabouret
Session: Proffered paper session: CNS tumours
Resources:
Slides
Webcast
Invited Discussant 799MO, 800MO and 801MO
Presenter: Sara Garrido Paniagua
Session: Mini oral session 1: Haematological malignancies
Resources:
Slides
Webcast
1786O - BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis (IA) of a randomized phase II study
Presenter: Ewa Kalinka
Session: Proffered Paper session: Non-metastatic NSCLC
Resources:
Abstract
Slides
Webcast